G. Defossez, L. Guyader-peyrou, S. Uhry, Z. Grosclaude, P. Colonna et al.,

, Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Synthèse, 2019.

. Ggc--unicancer, Quels gènes analyser face à un risque de cancer héréditaire du sein et de l'ovaire ?, 2017.

. Inca, Oncogénétique en 2017 -consultations et laboratoires, Février, 2019.

F. Eisinger, B. Bressac, D. Castaigne, P. Cottu, J. Lansac et al.,

, Bull Cancer (Paris). mars, vol.91, issue.3, pp.219-256, 2004.

. Inca, Cancer du sein -Quelles modalités de dépistage pour quelles femmes ?, 2015.

. Inca, Parcours global des cas index et apparentés en oncogénétique, 2018.

D. F. Easton, P. Pharoah, A. C. Antoniou, M. Tischkowitz, S. V. Tavtigian et al., Gene-panel sequencing and the prediction of breast-cancer risk, N Engl J Med. 4 juin, vol.372, issue.23, pp.2243-57, 2015.

R. Scully and D. M. Livingston, In search of the tumour-suppressor functions of BRCA1 and BRCA2, Nature, vol.23, issue.6811, pp.429-461, 2000.

A. Antoniou, P. Pharoah, S. Narod, H. A. Risch, J. E. Eyfjord et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am J Hum Genet. mai, vol.72, issue.5, pp.1117-1147, 2003.

S. Chen and G. Parmigiani, Meta-Analysis of BRCA1 and BRCA2 Penetrance, J Clin Oncol. 10 avr, vol.25, issue.11, pp.1329-1362, 2007.

N. Mavaddat, S. Peock, D. Frost, S. Ellis, R. Platte et al., Cancer Risks for BRCA1

, BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE, JNCI J Natl Cancer Inst. 5 juin, vol.105, issue.11, pp.812-834, 2013.

C. Corsini and P. Pujol, Oncogénétique des cancers pelviens

D. Sur,

L. Golmard, L. Castéra, S. Krieger, V. Moncoutier, K. Abidallah et al.,

, Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers, Eur J Hum Genet EJHG, vol.25, issue.12, pp.1345-53, 2017.

J. Thacker, A surfeit of RAD51-like genes?, Trends Genet TIG. mai, vol.15, issue.5, pp.166-174, 1999.

D. Schild, Y. C. Lio, D. W. Collins, T. Tsomondo, and D. J. Chen, Evidence for simultaneous protein interactions between human Rad51 paralogs, J Biol Chem. 2 juin, vol.275, issue.22, pp.16443-16452, 2000.

L. M. Pelttari, T. Heikkinen, D. Thompson, A. Kallioniemi, J. Schleutker et al., RAD51C is a susceptibility gene for ovarian cancer, Hum Mol Genet. 15 août, vol.20, issue.16, pp.3278-88, 2011.

L. M. Pelttari, J. Kiiski, R. Nurminen, A. Kallioniemi, J. Schleutker et al., A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer, J Med Genet. juill, vol.49, issue.7, pp.429-461, 2012.

C. Loveday, C. Turnbull, E. Ruark, R. Xicola, E. Ramsay et al., Germline RAD51C mutations confer susceptibility to ovarian cancer, Nat Genet. 26 avr, vol.44, issue.5, pp.475-481, 2012.

C. Loveday, C. Turnbull, E. Ramsay, D. Hughes, E. Ruark et al., Germline mutations in RAD51D confer susceptibility to ovarian cancer, Nat Genet. 7 août, vol.43, issue.9, pp.879-82, 2011.

J. Li, H. Meeks, B. Feng, S. Healey, H. Thorne et al., Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families, J Med Genet. janv, vol.53, issue.1, pp.34-42, 2016.

H. Song, E. Dicks, S. J. Ramus, J. P. Tyrer, M. P. Intermaggio et al., Contribution of
URL : https://hal.archives-ouvertes.fr/hal-01460107

, Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population, J Clin Oncol Off J Am Soc Clin Oncol. 10 sept, vol.33, issue.26, pp.2901-2908, 2015.

G. Bougeard, M. Renaux-petel, J. Flaman, C. Charbonnier, P. Fermey et al.,

, Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers, J Clin Oncol. 20 juill, vol.33, issue.21, pp.2345-52, 2015.

D. Malkin, F. P. Li, L. C. Strong, J. F. Fraumeni, C. E. Nelson et al., Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms, Science, vol.250, issue.4985, pp.1233-1241, 1990.

. Unicancer-groupe-génétique, V. Cancer-;-bubien, F. Bonnet, V. Brouste, S. Hoppe et al., High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome, J Med Genet, 2017.

M. Tan, J. L. Mester, J. Ngeow, L. A. Rybicki, M. S. Orloff et al., Lifetime Cancer Risks in Individuals with Germline PTEN Mutations, Clin Cancer Res. 15 janv, vol.18, issue.2, pp.400-407, 2012.

D. L. Riegert-johnson, F. C. Gleeson, M. Roberts, K. Tholen, L. Youngborg et al.,

, Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients, Hered Cancer Clin Pract. 17 juin, vol.8, issue.1, p.6, 2010.

P. Pharoah, P. Guilford, and C. Caldas, Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families

, Gastroenterology. 1 déc, vol.121, issue.6, pp.1348-53, 2001.

E. R. Thompson, S. M. Rowley, N. Li, S. Mcinerny, L. Devereux et al.,

, Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai, vol.34, issue.13, pp.1455-1464, 2016.

A. C. Antoniou, S. Casadei, T. Heikkinen, D. Barrowdale, K. Pylkäs et al., Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review, Gastroenterology. mai, vol.371, issue.6, pp.1535-1584, 1993.

V. Bonadona, B. Bonaïti, S. Olschwang, S. Grandjouan, L. Huiart et al., Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome, JAMA. 8 juin, vol.305, issue.22, pp.2304-2314, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00780536

M. Kempers, R. P. Kuiper, C. W. Ockeloen, P. O. Chappuis, P. Hutter et al., Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study, Lancet Oncol. janv, vol.12, issue.1, pp.49-55, 2011.

S. E. Plon, D. M. Eccles, D. Easton, W. D. Foulkes, M. Genuardi et al.,

, Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat, vol.29, pp.1282-91, 2008.

S. Richards, N. Aziz, S. Bale, D. Bick, and S. Das, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, On behalf of the ACMG Laboratory Quality Assurance Committee, vol.17, pp.405-428, 2015.

D. E. Goldgar, D. F. Easton, A. M. Deffenbaugh, A. Monteiro, S. V. Tavtigian et al.,

, Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2, Am J Hum Genet, vol.75, issue.4, pp.535-579, 2004.

G. Chenevix-trench, S. Healey, S. Lakhani, P. Waring, M. Cummings et al.,

, Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance, Cancer Res. 15 févr, vol.66, issue.4, pp.2019-2046, 2006.

D. F. Easton, A. M. Deffenbaugh, D. Pruss, C. Frye, R. J. Wenstrup et al., A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes, Am J Hum Genet, vol.81, issue.5, pp.873-83, 2007.

S. V. Tavtigian, G. B. Byrnes, D. E. Goldgar, and A. Thomas, Classification of rare missense substitutions, using risk surfaces, with genetic-and molecular-epidemiology applications, Hum Mutat, vol.29, issue.11, pp.1342-54, 2008.

N. M. Lindor, L. Guidugli, X. Wang, M. P. Vallée, A. Monteiro et al., A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS), Hum Mutat. janv, vol.33, issue.1, pp.8-21, 2012.

L. A. Korde, C. M. Mueller, J. T. Loud, J. P. Struewing, K. Nichols et al., No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families, Breast Cancer Res Treat. 1 janv, vol.125, issue.1, pp.169-73, 2011.

H. A. Katki, M. H. Gail, and M. H. Greene, Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families, Lancet Oncol. 1 déc, vol.8, issue.12, pp.1042-1045, 2007.

K. A. Metcalfe, A. Finch, A. Poll, D. Horsman, C. Kim-sing et al., Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation, Br J Cancer. janv, vol.100, issue.2, pp.421-426, 2009.

C. Béroud, S. I. Letovsky, C. D. Braastad, S. M. Caputo, O. Beaudoux et al., BRCA Share: A Collection of Clinical BRCA Gene Variants, Hum Mutat, vol.37, issue.12, pp.1318-1346, 2016.

P. J. Vail, B. Morris, A. Van-kan, B. C. Burdett, K. Moyes et al., Comparison of locus-specific databases for BRCA1 and BRCA2 variants reveals disparity in variant classification within and among databases, J Community Genet, vol.6, issue.4, pp.351-360, 2015.

N. M. Lindor, D. E. Goldgar, S. V. Tavtigian, S. E. Plon, and F. J. Couch, BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management, The Oncologist, vol.18, issue.5, pp.518-542, 2013.

K. Ready, A. M. Gutierrez-barrera, C. Amos, F. Meric-bernstam, K. Lu et al.,

H. Autorité-de-santé, Haute Autorité de santé 2014 -Dépistage du cancer du sein en France : identification des femmes à haut risque et modalités de dépistage Synthèse

. Inca, Synthèse -Femmes porteuses d'une mutation de BRCA1 ou BRCA2 /Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque, 2017.

A. C. Antoniou, A. P. Cunningham, J. Peto, D. G. Evans, F. Lalloo et al., The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions, Br J Cancer. 22 avr, vol.98, issue.8, pp.1457-66, 2008.

E. B. Claus, N. Risch, and W. D. Thompson, Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction, Cancer. 1 févr, vol.73, issue.3, pp.643-51, 1994.

D. A. Berry, E. S. Iversen, D. F. Gudbjartsson, E. H. Hiller, J. E. Garber et al.,

, BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes, J Clin Oncol Off J Am Soc Clin Oncol. 1 juin, vol.20, issue.11, pp.2701-2713, 2002.

J. Tyrer, S. W. Duffy, and J. Cuzick, A breast cancer prediction model incorporating familial and personal risk factors, Stat Med. 15 avr, vol.23, issue.7, pp.1111-1141, 2004.

A. De-pauw, D. Stoppa-lyonnet, N. Andrieu, and B. Asselain, Estimation of individual breast cancer risk: relevance and limits of risk estimation models

, Bull Cancer (Paris), vol.96, pp.979-88, 2009.

D. G. Evans, K. N. Gaarenstroom, D. Stirling, A. Shenton, L. Maehle et al.,

, Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers, J Med Genet. sept, vol.46, issue.9, pp.593-600, 2009.

C. Y. Fang, C. Cherry, K. Devarajan, T. Li, J. Malick et al., A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer, Gynecol Oncol, vol.112, issue.3, pp.594-600, 2009.

M. V. Lee, V. S. Katabathina, M. L. Bowerson, M. I. Mityul, A. S. Shetty et al., BRCAassociated Cancers: Role of Imaging in Screening, Diagnosis, and Management, vol.37, pp.1005-1028, 2017.

B. Hermsen, R. I. Olivier, R. Verheijen, M. Van-beurden, J. A. De-hullu et al., No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study, Br J Cancer. 7 mai, vol.96, issue.9, pp.1335-1377, 2007.

L. C. Hartmann, D. J. Schaid, J. E. Woods, T. P. Crotty, J. L. Myers et al., Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, N Engl J Med. 14 janv, vol.340, issue.2, pp.77-84, 1999.

M. H. Frost, D. J. Schaid, T. A. Sellers, J. M. Slezak, P. G. Arnold et al., Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy

, JAMA. 19 juill, vol.284, issue.3, pp.319-343, 2000.

S. M. Domchek, T. M. Friebel, C. F. Singer, D. G. Evans, H. T. Lynch et al., Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality

, JAMA. 1 sept, vol.304, issue.9, pp.967-75, 2010.

A. Finch, K. A. Metcalfe, J. K. Chiang, L. Elit, J. Mclaughlin et al., The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation, Gynecol Oncol. 1 avr, vol.121, issue.1, pp.163-171, 2011.

M. Gingras and H. Belleau, Avantages et désavantages du sondage en ligne comme méthode de collecte de données : une revue de la littérature, vol.21, 2015.

S. A. Feig and R. E. Hendrick, Radiation risk from screening mammography of women aged 40-49 years, J Natl Cancer Inst Monogr, vol.22, pp.119-143, 1997.

A. Berrington-de-gonzalez, C. D. Berg, K. Visvanathan, and M. Robson, Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers, J Natl Cancer Inst. 4 févr, vol.101, issue.3, pp.205-214, 2009.

M. Frankenberg-schwager and A. Gregus, Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers

, Int J Radiat Biol, vol.88, issue.11, pp.846-57, 2012.

B. K. Eccles, E. Copson, T. Maishman, J. E. Abraham, and D. M. Eccles, Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer, vol.15, p.936, 2015.